now vaccine up........bio sleep......kikikikikih

follow up or down........normally down......kikikikikikih

negram pun, tak payah ada thunder.....tiba2 je naik nanti......kikikikikikikih

tat tau ,air dah masuk rumah.......kikikikikikih

sana hujan lebat tu, tarak thunder pun.....kikikikikih

tarak hujan apa....orang dah dok kalut banjir tu boss.......kikikikikih

boss tak suka glamour.......kikikikikih

wowww.....stocks otai

o & g??......bila nak beranak.....kikikikiih

NEXGRAM HOLDINGS BERHAD (“NEXGRAM” OR “COMPANY”)
REPLY TO QUERY LETTER FROM BURSA MALAYSIA SECURITIES BERHAD DATED 14
DECEMBER 2020 (REF : IQL-14122020-00001)
SUBJECT : OTHERS
DESCRIPTION : NEXGRAM HOLDINGS BERHAD (“NEXGRAM” OR “THE
COMPANY”)
MASTER STRATEGIC JOINT VENTURE AGREEMENT
BETWEEN VACCINES LAB SDN BHD (“VACCINESLAB”), A
WHOLLY-OWNED SUBSIDIARY OF NEXGRAM HOLDINGS
BERHAD, WITH RAFARMA PHARMACEUTICALS INC.
(“RAFARMA”)
The Company’s announcement dated 10 December 2020 (“Announcement”) and the query
letter from Bursa Malaysia Securities Berhad dated 14 December 2020 (Ref : IQL-14122020-
00001) in relation to the Master Strategic Joint Venture Agreement (“Agreement”) refer.
Unless otherwise stated, the terms used in this announcement shall have the same meaning
as defined in the Announcement.
The Board of Directors of Nexgram wishes to announce the following additional information
as required in Query:
1. The proposed principal activities of the joint venture company (“JVC”)
The principal activities of the JVC are sourcing and distributing of vaccines to ASEAN
markets, with option to build up vaccine manufacturing plant in Indonesia.
2. The capital and investment outlay by VaccinesLab in the JVC, its sources of
funding and the breakdown.
The joint venture plant would cost approximately USD250 million for phase 1, and in
principle is fully funded by major shareholder Rafarma and its group of investors to be
identified. Details of pre-operation cost is currently under negotiation.
3. The relevant regulatory approvals required to be obtained by the JVC before it
can commence its operations.
The main law providing for manufacturing, licensing and sale of pharmaceutical
products is the Regulation No. 1010/XI/2008 on Registration of Medicines issued by
the Ministry of Health of Indonesia. All activities of pharmaceutical companies
registered in Indonesia are supervised by the Food and Medicine Supervisory Board
(“BPOM”). The Group through subsidiary PT NDS Global Teknologi in Indonesia shall
engage professional specialise in feasibility study and registration studies with BPOM.
4. The equity interest to be subscribed by VaccineLabs in the JVC.
Except Group existing operation cost (Opex), the Group shall allocate approximately
USD1 million and pre-operation cost for feasibility study and registration through
internal generated fund. Capital Expenditure (Capex) is as per Q2 above, currently
under negotiation.
5. Please provide further information on RAFARMA including the shareholders,
board of directors, senior management and listing status (if RAFARMA is listed).
The main shareholder is IIya Shpurov who holds 91.3% of RAFARMA. The board of
directors are:-
i. Ilya Shpurov;
ii. Srecko Bojt; and
iii. Vladimir G. Dolgolenko (who is also the CEO of RAFARMA).
6. Pertaining to the Parties’ desire to develop and conduct the Clinical Trial and
invest in the Vaccine Plant, please clarify how does RAFARMA intend to strive
for access to the Covid-19 vaccines for use/test/distribution, i.e. whether
RAFARMA intends to source for the said vaccines or intends to develop the said
vaccines. To also clarify the current stage of acquisition/development of the
Covid-19 vaccines.
According to RAFARMA, they are working with one of a Russian national
pharmaceutical pioneer established since 1959 with strong research and development
team for vaccine research and development in the long-term; where as its existing
network with Russian government and European pharmaceutical companies in terms
of sourcing, distribution and conduct clinical trial for established vaccines in the shortterm. Details of the plan are currently under discussion between RAFARMA and
VaccinesLab advisors.
7. Please clarify what are the expected or agreed milestones with regard to Clinical
Trial and Vaccine Plant.
Disclosable long-term milestones are as per Q6 above. Currently the companies had
formed regular studies and evaluation discussions team between RAFARMA and
VaccinesLab advisors on WHO’s listed Covid-19 vaccine clinical trial results especially
in terms of safety and efficacy, as well as comparing the research with Russian
vaccines currently under various stages of studies, including phase 1 to 3 clinical trials.
The team shall propose to VaccinesLab the relevant vaccines deem suitable for
ASEAN market in line with WHO updates and standards.
8. Please clarify the source of funding and/or arrangement through which
RAFARMA intends to secure the USD1 billion investment.
The joint venture plant in principle is fully funded by major shareholder RAFARMA and
its group of investors to be identified. Details of the funding structure is currently under
midst of discussion.

https://malaysiastock.biz/Company-Announcement.aspx?id=1281817

sudah ramai fed up and frust menonggeng.....kikikikikih

jual ....jangan tak jual.......kikikikikikikih

rewards only for patient traders......kikikikikih
15/12/2020 2:46 PM
++++++

smart MZM2511 oledi RUNNNNNNNNN for his life.....
those remained here risk of left with tulang tongkeng....
15/12/2020 3:25 PM

----------------------------------------------------------------

will see.......kikikikikih

sudah ramai fed up and frust menonggeng.....kikikikikih

jual ....jangan tak jual.......kikikikikikikih

rewards only for patient traders......kikikikikih

https://www.theedgemarkets.com/article/nexgram-inks-partnership-us-drug-manufacturer-supply-vaccines-indonesia

https://klse.i3investor.com/blogs/kianweiaritcles/2020-12-10-story-h1537510528-Indonesia_secures_155_5_million_doses_of_Covid_19_vaccine_seeks_116_mil.jsp

VACCINESLAB and RAFARMA desire to jointly develop and conduct initial
clinical trial and expanded clinical trial (“Clinical Trial”) and invest in LARGESCALE COVID-19 VACCINE FACILITY IN INDONESIA (“Vaccine Plant”)
exclusively for the above and other various vaccines as well as other immunological
promising drug, use developed by RAFARMA, especially clinical trials in regional
trial sites outside of USA and China with this MSJVA.


ni bukan nak just jadi distributor......BUT NAK BUKAK PLANT TU.......kikikikikih

tuju langit nexgrammmmmm........kikikikikikih

https://malaysiastock.biz/Company-Announcement.aspx?id=1280888

intel buy?? cheap stock always a cheap stock..
10/12/2020 1:46 PM

-------------------------------------

dont you know that what happened to cheap stock like skpres....frontkn...careplus...solution...inari....hwgb...kikikikikikikih

opportunity .......beliiiiiiiii.......kikikikikih

pagi tadi ada orang kato....bursa mau collapse...cheap sale......menipu rupanya.....kikikikikih

woowwwww...its BLOODY GOOD MONDAY..........kikikikikikih

mzm2511......dont be too stressful with oku 2020 attitude.....that's normal for every thread....sure got 1 or 2 sougrapes....accept it as part of entertainment........kikikikikikih

well 186m shares left....dont worry guys...once vol come in like 300-400m....186 only like ikan bilis....dont too worry about it......in 1 day that vol. will swallow ozura.....just wait....time will come.....kikikikikikih

actually 'boss' tried to test the patience of ozura.....kikikikikikikih

kikikikikikih.......tak tahan jual je.......great reward for super patience people.....

kikikikikikih

oku2020 also missing already ......must be tired kutuk nexgram........kikikikikikikikih

ya lar....sudah tarak kerja....isi masa lapang here lor.....kikikikikih

if this news come from mtouche or kanger or solution or bintai....sure that counter limit up.....kikikikikih

normally when really quiet.....something are coming but this nexgram......aaadddoooi susah nak kata....kikikikikih

naik geram apa tu....tengok orang atas katil ke??.........kikikikikih

any of us have skill to write blog??.....that's one way to promote nexgram to public....like calvin...bursamaster....

hold tight2 and peram lama2......kasi tapai masak betul2.....kjikikikikikih

other company even directors kahwin 2 also pun in media.....kikikikikih

anyway i prefer to hold price here until that ah long(ozura) clear from this stock.....kikikikikih

management should give media release for public to know....you can count with fingers only, people who read or go to nexgram website.....i also dont know if mzm2511 didnt post it here.....aaaaaddddoooiiiiiiiiii

or maybe this part of game to let ozura dispose first...then they will start push up......kikikikikih

one of good news is if management can make official announcement about how many test kit been used to help country fight covid 19'....

5sen...nothing for big speculators/traders....kikikikikikih

actually ozura is nothing...but sideliners need some prove that their projects really productive...that's all....when vol. come...ozura just like ikan bilis only.....kikikikikih

seen last week ,anytime big shares unloaded by someone....straightaway sapu by another party....hopefully good sign of accumulation...just tell your heart to be patience

hopefully some good shareholders picked their shares.....kikikikikih

may be got to wait another 1 year to habis.......aaaaaddddooooiii

kkkiiikikikih

big mistake for the company pinjam duit with this ah long.......aaaaddddoooooiiii

jual lagi......kikikikikikih....
sapa mau push up selagi this predator still around......kikikikikikih

orang sudah takut mau beli......hari2 ozura tunggu mau jual.......adooiiiii

nexgram suma ada.....cuma tak de buyer je.....kikikikikikih

good sentiments killed by ozura......they should sell it bit by bit so market wont feel it....not all in one go....really stupid....

directors bought at higher price.....when price dropped....for sure they will in any way will bring up the price again.....kikikikikih

driver sakit perut lagi......masuk toilet again.....kikikikih